z-logo
open-access-imgOpen Access
Molecular Profiling and Minimal Residual Disease Monitoring in Multiple Myeloma Patients: A Literature Review
Author(s) -
A. V. Semyanikhina,
E. E. Tolstykh
Publication year - 2021
Publication title -
kliničeskaâ onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.116
H-Index - 2
eISSN - 2500-2139
pISSN - 1997-6933
DOI - 10.21320/2500-2139-2021-14-4-436-443
Subject(s) - minimal residual disease , multiple myeloma , neoplasm , genome , transcriptome , disease , plasma cell neoplasm , computational biology , medicine , personalized medicine , somatic evolution in cancer , bioinformatics , oncology , biology , gene , pathology , cancer , genetics , gene expression , leukemia , plasmacytoma
A personalized approach is a promising tool for malignant neoplasm (MN) treatment. Gaining success and benefit assessment of this approach were considerably facilitated by the implementation of omix techniques which allow to obtain comprehensive information on the tumor genome and transcriptome state with identifying potential biomarkers and targets for directed drug action. Despite the exponential growth in the number of sequenced tumor genomes, some of them are not subject of active clinical studies, although obviously and increasingly require optimization of current treatment regimens. One of these pathologies is multiple myeloma (MM). Considerable advances in its diagnosis and treatment have substantially increased survival rates. However, MM cannot be removed from the list of fatal diseases, yet. It is a neoplasm which needs to be further studied and explored for implementation of new treatment strategies, most of which would be based on pheno- and genotypic characteristics of tumor cells. The present review deals with the state of the art in the study of the MM molecular genetic profile, minimal residual disease (MRD) monitoring as well as potentials of the new generation sequencing for MRD diagnosis, prognosis, estimation, and search for predictors aimed at chemotherapy optimization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here